Deliver Your News to the World

SuperStitch Successfully Introduced by Sutura Sales Team at TCT Convention in Washington, DC


WEBWIRE

Fountain Valley, CA – October 18, 2005 - Sutura, Inc. (OTCBB:SUTU) (“Sutura”), a California-based medical device company, announced the successful introduction of the ’As Simple As 1-2-3’ SuperStitch suturing device by the Company’s new expanded sales team at this week’s TCT Convention in Washington, DC. Sutura’s booth (#617) is located in the center of the convention floor along with most of the major medical device companies including some of its direct competitors. The Company is at the TCT Convention to enable its new expanded sales team to showcase the SuperStitch technology and generate leads from the thousands of cardiologists, radiologists, vascular medicine specialists, surgeons and other health care professionals in attendance.

“Our booth has been generating considerable excitement and energy in the vessel closure section at the conference,” said Anthony Nobles, CEO/President of Sutura. “Our sales team, which includes several experienced sales people Sutura has recently hired directly away from our competitors, believes the leads generated at the conference will translate into SuperStitch sales.”

Joining the Sutura team at the TCT conference are new sales representatives Kathy King and Mike Calamante.

“The ’As Simple As 1-2-3’ SuperStitch is clearly the next generation suturing device and is the reason I decided to become part of the Sutura sales team,” stated Mike Calamante, who came to Sutura after working for a competitive product for the past nine years. “I believe the SuperStitch technology is in a position to capture a large share of the vessel closure market, and I saw an opportunity to build a significant sales channel for the product across the country.”

About Transcatheter Cardiovascular Therapeutics (TCT)

Transcatheter Cardiovascular Therapeutics (TCT), sponsored by the Cardiovascular Research Foundation (CRF), is the world’s largest symposium for physicians and other health care professionals who specialize in the field of interventional vascular therapy. Held in the Washington Convention Center, this year’s TCT spans five days, from Sunday afternoon, October 16 through Friday afternoon, October 21, 2005. As in previous years, numerous groundbreaking and pioneering innovations relevant to clinical practice will be introduced at the meeting. More information on this year’s conference can be found at www.tct2005.com.

About Sutura, Inc.

Sutura®, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company’s line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.

Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura’s headquarters are in Fountain Valley, California. “Sutura®” and “SuperStitch®” are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or “forward-looking” information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words “aim”, “plan”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “estimate”, “will”, “should”, “could”, “may”, “appears”, and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed sales and marketing plan, the continued growth of the vessel closure marketplace and the company’s ability to continue to expand and protect its technology patents.

Sutura, Inc. (OTC Bulletin Board:SUTU)



WebWireID4802





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.